Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Journal article

BACKGROUND: We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia. METHODS: A total of 809 patients with essential thrombocythemia who were at high risk for vascular events received low-dose aspirin plus either anagrelide or hydroxyurea. The composite primary end point was the actuarial risk of arterial thrombosis (myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, or peripheral arterial thro...

Expand abstract

Authors: Harrison, C; Campbell, P; Buck, G; Wheatley, K; East, C

• Publication status: Published
• Journal: New England journal of medicine
• Volume: 353
• Issue: 1
• Pages: 33-45
• Publication date: 2005-07-01
• DOI: 10.1056/nejmoa043800
• EISSN: 1533-4406
• ISSN: 0028-4793
• Language: English
• Keywords: Thrombosis; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study; Follow-Up Studies; Aged; Platelet Aggregation Inhibitors; Adult; Aged, 80 and over; Leukemia, Myeloid, Acute; Drug Therapy, Combination; Middle Aged; Aspirin; Hydroxyurea; Hemorrhage; Primary Myelofibrosis; Male; Antineoplastic Agents; Thrombocythemia, Essential; Female; Humans; Platelet Count; Quinazolines